Investigational Studies

Copyright © 2019 Haymarket Media, Inc. All Rights Reserved This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media’s Privacy Policy and Terms Conditions. … read more at: https://www.empr.com/home/news/linagliptin-non-inferior-to-glimepiride-in-long-term-cardiovascular-outcome-study/

Copyright © 2019 Haymarket Media, Inc. All Rights Reserved This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media’s Privacy Policy and Terms Conditions. … read more at: https://www.empr.com/home/news/biosimilar-retacrit-an-erythropoiesis-stimulating-agent-now-available/

Copyright © 2019 Haymarket Media, Inc. All Rights Reserved This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media’s Privacy Policy and Terms Conditions. … read more at: https://www.empr.com/home/news/biosimilar-retacrit-an-erythropoiesis-stimulating-agent-now-available/

Copyright © 2019 Haymarket Media, Inc. All Rights Reserved This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media’s Privacy Policy and Terms Conditions. … read more at: https://www.empr.com/home/news/elzonris-infusion-approved-for-aggressive-rare-blood-disease/

Copyright © 2019 Haymarket Media, Inc. All Rights Reserved This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media’s Privacy Policy and Terms Conditions. … read more at: https://www.empr.com/home/news/elzonris-infusion-approved-for-aggressive-rare-blood-disease/

Copyright © 2019 Haymarket Media, Inc. All Rights Reserved This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media’s Privacy Policy and Terms Conditions. … read more at: https://www.empr.com/home/news/drugs-in-the-pipeline/lonafarnib-gets-breakthrough-tx-designation-for-progeria-progeroid-laminopathies/

Copyright © 2019 Haymarket Media, Inc. All Rights Reserved This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media’s Privacy Policy and Terms Conditions. … read more at: https://www.empr.com/home/news/drugs-in-the-pipeline/lonafarnib-gets-breakthrough-tx-designation-for-progeria-progeroid-laminopathies/

Copyright © 2019 Haymarket Media, Inc. All Rights Reserved This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media’s Privacy Policy and Terms Conditions. … read more at: https://www.empr.com/home/news/drugs-in-the-pipeline/soliris-gets-priority-review-for-rare-complement-mediated-cns-disorder/

Copyright © 2019 Haymarket Media, Inc. All Rights Reserved This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media’s Privacy Policy and Terms Conditions. … read more at: https://www.empr.com/home/news/drugs-in-the-pipeline/soliris-gets-priority-review-for-rare-complement-mediated-cns-disorder/

Copyright © 2019 Haymarket Media, Inc. All Rights Reserved This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media’s Privacy Policy and Terms Conditions. … read more at: https://www.empr.com/home/news/new-fda-approved-treatment-significantly-reduces-infarct-size-in-mi-patients/

Copyright © 2019 Haymarket Media, Inc. All Rights Reserved This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media’s Privacy Policy and Terms Conditions. … read more at: https://www.empr.com/home/news/new-fda-approved-treatment-significantly-reduces-infarct-size-in-mi-patients/

Copyright © 2019 Haymarket Media, Inc. All Rights Reserved This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media’s Privacy Policy and Terms Conditions. … read more at: https://www.empr.com/home/news/first-rituximab-biosimilar-truxima-gets-fda-approval/

Copyright © 2019 Haymarket Media, Inc. All Rights Reserved This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media’s Privacy Policy and Terms Conditions. … read more at: https://www.empr.com/home/news/drugs-in-the-pipeline/pexidartinib-gets-priority-review-for-tenosynovial-giant-cell-tumor/

Copyright © 2019 Haymarket Media, Inc. All Rights Reserved This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media’s Privacy Policy and Terms Conditions. … read more at: https://www.empr.com/home/news/drugs-in-the-pipeline/caplacizumab-cuts-time-to-platelet-count-normalization-in-attp-patients/

The Food and Drug Administration (FDA)’s Psychopharmacologic Drug Advisory Committee and Drug Safety and Risk Management Advisory Committee voted in favor (14 yes, 2 no, 1 abstain) of the approval of esketamine nasal spray (Spravato; Janssen) for the treatment of adult patients with treatment-resistant depression (TRD). The decision was based on data from five Phase […]